Format

Send to

Choose Destination
J Zhejiang Univ Sci B. 2012 Sep;13(9):731-44.

Efficacy and safety of rituximab therapy for systemic lupus erythematosus: a systematic review and meta-analysis.

Author information

1
Department of Kidney Disease Center, the First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou 310003, China.

Abstract

OBJECTIVE:

To review the efficacy and safety of rituximab therapy for systemic lupus erythematosus (SLE).

METHODS:

We searched for randomized controlled trails and observational studies that evaluated the effect of rituximab based on the systemic lupus erythematosus disease activity index (SLEDAI), British Isles lupus assessment group index (BILAG), urine protein levels, and the prednisolone dose, and had adequate data to calculate the mean, standard deviation (SD), and 95% confidence intervals, and to systematically review and meta-analyze observational studies with fixed effects model or random effects model.

RESULTS:

We included 2 randomized controlled studies and 19 observational clinical studies. We summarized the data from the 19 observational studies, analyzed the heterogeneity of the literature, and then used fixed effect model or random effect model for statistical analysis. The SLEDAI, BILAG, and urine protein levels and the prednisolone dosage were decreased after rituximab treatment, and the decreases in the BILAG, urine protein levels, and the prednisolone dose were found to be significant (P<0.05), when compared with baseline level. Rituximab's adverse effects generally could be controlled with an effective dosing regimen.

CONCLUSIONS:

Although there are still controversies about rituximab's treatment on SLE, but our study had showed that rituximab had favorable effects on refractory lupus. The long-term efficacy and safety of rituximab require further study.

PMID:
22949364
PMCID:
PMC3437371
DOI:
10.1631/jzus.B1200057
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Zhejiang University Press Icon for PubMed Central
Loading ...
Support Center